AC Immune SA | CIK:0001651625 | 3

  • Filed: 3/20/2018
  • Entity registrant name: AC Immune SA (CIK: 0001651625)
  • Generator: EDGARfilings PROfile
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/0000950103-18-003508-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/aciu-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001651625
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory

    22.
    Capital risk management

    The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against AD.